Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback